Hydroxychloroquine dose based upon weight and renal function

Discussion in 'Chloroquine Drug' started by Vasiley, 18-Mar-2020.

  1. A_Liss New Member

    Hydroxychloroquine dose based upon weight and renal function


    Falciparum Discontinue in 6 months if improvement is inadequate Use in patients with psoriasis may precipitate a severe attack of psoriasis; use with caution Postmarketing cases of life-threatening and fatal cardiomyopathy reported with use of hydroxychloroquine as well as of chloroquine Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease Ocular examination is recommended within first year of therapy; baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT) For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT; for individuals without significant risk factors, annual exams can usually be deferred until five years of treatment In individuals of Asian descent, retinal toxicity may first be noticed outside macula; in patients of Asian descent, it is recommended that visual field testing be performed in central 24 degrees instead of central 10 degrees Hydroxychloroquine should be discontinued if ocular toxicity is suspected and patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy Hepatic disease or alcoholism Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with hemolysis and renal impairment; use with caution Dermatologic reactions to hydroxychloroquine may occur Patients are prone to dermatitis outbreaks Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment; clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during therapy; if cardiotoxicity is suspected, prompt discontinuation may prevent life-threatening complications Not for administration with other drugs that have potential to prolong QT interval; hydroxychloroquine prolongs QT interval; ventricular arrhythmias and torsades de pointes reported in patients taking hydroxychloroquine Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, reported; muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes; assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy Suicidal behavior rarely reported in patients treated with hydroxychloroquine Hematologic reactions (including aplastic anemia) and agranulocytosis may occur May exacerbate heart failure Shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications; warn patients about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment should have their blood glucose checked and treatment reviewed as necessary A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs Use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs Consider discontinuing therapy if any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, which is not attributable to the disease under treatment appears; perform periodic blood cell counts if patients are given prolonged therapy Pregnancy category: C Lactation: Drug is concentrated in breast milk (American Academy of Pediatrics committee states that it is compatible with nursing) A: Generally acceptable. Contact the applicable plan provider for the most current information. Controlled studies in pregnant women show no evidence of fetal risk. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Animal studies show risk and human studies not available or neither animal nor human studies done.

    Plaquenil and risperdal Chloroquin phosphate site drugs.com What is plaquenil medication used for

    Note This document contains side effect information about hydroxychloroquine. Some of the dosage forms listed on this page may not apply to the brand name Plaquenil. For the Consumer. Applies to hydroxychloroquine oral tablet. Along with its needed effects, hydroxychloroquine the active ingredient contained in Plaquenil may cause some unwanted effects. There were no differences in hydroxychloroquine levels when both height and ideal body weight were compared across the different blood concentrations. This suggests that we are correctly dosing patients based on actual rather than ideal body weight not exceeding a dose of 400 mg per day and indicated that dosing based on height is unnecessary. Irreversible retinal damage observed in some patients who had received hydroxychloroquine sulfate; significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg 5 mg/kg base of actual body weight, durations of use greater than five years, subnormal glomerular filtration.

    Unknown; may impair complement-dependent antigen-antibody reactions; inhibits locomotion of neutrophils and chemotaxis of eosinophils Increases p H and interferes with lysosomal degradation of hemoglobin, which in turn interferes with digestive vacuole function Bioavailability: Rapid and complete absorption Onset: May take 4-6 months to show response; peak response takes several months (rheumatic disease) Duration: Unknown Peak plasma time: 1-3 hr Protein bound: 55% Metabolites: Desethylhydroxychloroquine, desethylchloroquine Half-life: 32-50 days Excretion: Urine (60%) The above information is provided for general informational and educational purposes only. D: Use in LIFE-THREATENING emergencies when no safer drug available.

    Hydroxychloroquine dose based upon weight and renal function

    Plaquenil Risk Calculators, Hydroxychloroquine Blood Levels in Systemic Lupus.

  2. Can hydroxychloroquine cause weight loss
  3. What happens if you take too much plaquenil
  4. Dosages of drugs cleared renally are based on renal function calculated as GFR or creati-nine clearance; Table 3. These calculations are valid only when renal function is stable

    • Drug Dosing Adjustments in Patients with Chronic Kidney Disease.
    • Plaquenil hydroxychloroquine sulfate dosing, indications..
    • DailyMed - HYDROXYCHLOROQUINE SULFATE tablet, film coated.

    All patients in the cohort were prescribed hydroxychloroquine not to exceed a dose of 6.5 mg per kilogram. The maximum daily dose prescribed is 400 mg. In those who are on hemodialysis 200 mg was prescribed after each dialysis session. In those with renal insufficiency, the dose was 200mg daily. Weight based dosage in adults and pediatric patients 13 mg/kg 10 mg/kg base, not to exceed 800 mg 620 mg base followed by 6.5 mg/kg 5 mg/kg base, not to exceed 400 mg 310 mg base, at 6 hours, 24 hours and 48 hours after the initial dose. Hydroxychloroquine Sulfate film-coated tablets cannot be divided, therefore they should not be used. Apr 03, 2016 Regarding the dosing of hydroxychloroquine, we advocate the use of a weight-based dosing regimen with a cap at 400 mg per day, except in the case of renal insufficiency, when the dose should be reduced to 200 mg per day and for those on dialysis, who should take their hydroxychloroquine at 200 mg three times per week.

     
  5. cheapcidazz XenForo Moderator

    Chloroquine is the generic form of the brand-name prescription medicine Aralen, which is used to prevent and treat malaria — a mosquito-borne disease caused by a parasite — and to treat amebiasis, an infection of the intestines caused by a parasite. APExBIO - Chloroquine diphosphateAntimalarial drugCAS# 50-63-5 CHLOROQUINE sulfate or phosphate oral - Essential drugs Chloroquine diphosphate C18H32ClN3O8P2 ChemSpider
     
  6. 042 Guest

    Hydroxychloroquine Reviews Everyday Health Plaquenil has been a life-saving drug for me, quite literally. I was a mess in 2004-2005 and then a dr put me on Plaquenil, and in 3 weeks most of my symptoms had disappeared.

    Plaquenil - Uses, Side Effects, Interactions -
     
  7. alexa1111 User

    Plaquenil Oral Interactions with Other Medication Does Plaquenil Interact with other Medications. nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare.

    Plaquenil Oral Uses, Side Effects, Interactions.